← back to search

Lori E. Dodd

National Institute of Allergy and Infectious Diseases · US
Area of research
Infectious Diseases · Statistics and Probability
Research interest
Research interests include Statistical Methods in Clinical Trials, Tuberculosis Research and Epidemiology, Infectious Diseases and Tuberculosis, and Health Systems, Economic Evaluations, Quality of Life.
h-index
40
citations
48,028
works
145
NIH funding
primary concept
Medicine
email

Recent publications

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.
2026cited by 0position: contributordoi
Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
2025cited by 56position: contributordoi
Three Cases of Vertical Transmission of Clade Ib Mpox Virus
New England Journal of Medicine 2025cited by 9position: middledoi
Three Cases of Vertical Transmission of Clade Ib Mpox Virus.
2025cited by 5position: contributordoi
Group‐Sequential Designs With an Externally‐Driven Change of Primary Endpoint
Statistics in Medicine 2025cited by 0position: middledoi
Group-Sequential Designs With an Externally-Driven Change of Primary Endpoint.
2025cited by 0position: contributordoi
CAnceR IN PreGnancy (CARING) – a retrospective study of cancer diagnosed during pregnancy in the United Kingdom
British Journal of Cancer 2024cited by 13position: middledoi
Group sequential designs for clinical trials when the maximum sample size is uncertain
Statistics in Medicine 2024cited by 0position: middledoi
Group sequential designs for clinical trials when the maximum sample size is uncertain.
2024cited by 0position: contributordoi
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
The Lancet Respiratory Medicine 2023cited by 123position: middledoi
Counting Monkeypox Lesions in Patient Photographs: Limits of Agreement of Manual Counts and Artificial Intelligence.
2023cited by 4position: contributordoi
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
The Lancet Respiratory Medicine 2022cited by 127position: middledoi
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis.
2021cited by 39position: contributordoi
How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.
2021cited by 0position: contributordoi
Endpoints for randomized controlled clinical trials for COVID-19 treatments.
2020cited by 57position: contributordoi
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
PLoS Medicine 2019cited by 109position: middledoi
A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups
Science Translational Medicine 2019cited by 32position: firstdoi
A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups.
2019cited by 20position: contributordoi
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
Gates Open Research 2017cited by 45position: middledoi
Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure
Nature Medicine 2016cited by 310position: middledoi
Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological Issues for Conducting and Reporting Research Evaluations of Tuberculosis Diagnostics for Intrathoracic Tuberculosis in Children. Consensus From an Expert Panela
The Journal of Infectious Diseases 2012cited by 115position: middledoi
Evaluating Imaging and Computer-aided Detection and Diagnosis Devices at the FDA
Academic Radiology 2012cited by 82position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 8 papers (2019–2025)Thomas Jaki · OTH Regensburg5 papers (2020–2025)Peter Horby · Johns Hopkins Hospital4 papers (2019–2025)Dean Follmann · Meridian Clinical Research4 papers (2019–2021)Peter Horby · University of Oxford3 papers (2019–2025) · 3 papers (2020–2025)Laurens Liesenborghs · Research Institute for Tropical Medicine2 papers (2025–2025)Nigel Stallard · University of Warwick2 papers (2024–2025) · 2 papers (2024–2025)Nigel Stallard · Amsterdam UMC Location Vrije Universiteit Amsterdam2 papers (2024–2025)Henry Clifford Lane · Analysis Group (United States)2 papers (2019–2025) · 2 papers (2023–2025)Amin Yarahmadi · University Hospitals Coventry and Warwickshire NHS Trust2 papers (2024–2025)Jason Kindrachuk · University of Saskatchewan1 papers (2025–2025)Katherine Fielding · Austin Hospital1 papers (2019–2019)Heang‐Ping Chan · Icahn School of Medicine at Mount Sinai1 papers (2012–2012)Andreas H. Diacon · Task Applied Science1 papers (2021–2021)Susanne Krasemann · University Medical Center Hamburg-Eppendorf1 papers (2025–2025)France Mentré · Inserm1 papers (2020–2020)Aurélie Gouél‐Cheron · Université Claude Bernard Lyon 11 papers (2019–2019)